---
title: Subcutaneous Administration of a Monoclonal Antibody to Prevent Malaria
date: '2024-04-26'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38669354/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&fc=20211015124055&ff=20240427180603&v=2.18.0.post9+e462414
source: N Engl J Med
description: 'CONCLUSIONS: Subcutaneous administration of L9LS to children was protective
  against P. falciparum infection and clinical malaria over a period of 6 months.
  (Funded by the National Institute of Allergy and Infectious Diseases; ClinicalTrials.gov
  number, ...'
disable_comments: true
---
CONCLUSIONS: Subcutaneous administration of L9LS to children was protective against P. falciparum infection and clinical malaria over a period of 6 months. (Funded by the National Institute of Allergy and Infectious Diseases; ClinicalTrials.gov number, ...